查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1800821

2025-2033年肺动脉高压药物市场报告（依药物类别、给药途径、最终用户和地区划分）

Pulmonary Arterial Hypertension Drugs Market Report by Drug Class, Route of Administration, End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 144 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球肺动脉高压 (PAH) 药物市场规模达80亿美元。展望未来， IMARC Group预计到2033年，该市场规模将达到120亿美元，2025-2033年期间的复合年增长率 (CAGR) 为4.4%。该市场正在经历显着成长，主要得益于标靶疗法的进步、PAH盛行率的上升以及公众意识的提升。不断扩大的研发投入也为全球市场带来了正面的前景。

肺动脉高压药物市场趋势：

联合疗法的应用增加

医生越来越多地采用联合疗法来提高肺动脉高压 (PAH) 的治疗效果。透过混合使用不同治疗类别的药物，医生可以针对 PAH 所涉及的多种生物学途径。这种多层面的方法有助于更有效地控制症状、减缓疾病进展并改善患者的整体预后。此外，联合疗法可以降低单一药物的剂量，从而可能减少副作用并提高患者的依从性。由于临床证据支持其益处，联合疗法正成为 PAH 管理的标准治疗方法，推动市场成长和创新。例如，2024 年 3 月，强生公司的 OPSYNVI(R)（马西替坦和他达拉非）获得美国 FDA 批准，成为首个针对成人肺动脉高压 (PAH) 的每日一次单片联合疗法。此项批准基于成功的 3 期 A 阶段 DUE 研究，该研究显示肺血流动力学显着改善。 OPSYNVI(R) 将两种成熟的治疗方法结合成一片药片，符合早期合併治疗的临床指引建议。

创新疗法日益受到关注

人们对肺动脉高压 (PAH) 创新疗法的日益关注，推动了基因疗法和标靶生物製剂的探索，旨在解决该疾病的根本原因。基因疗法有望改变与 PAH 相关的遗传因素，提供长期解决方案，而不仅仅是控制症状。另一方面，标靶生物製剂则专注于导致疾病进展的特定分子通路，从而实现更个人化、更有效的治疗。这些创新方法有望在疾病改良方面取得重大突破，提高 PAH 患者的存活率和整体生活品质。同时，Liquidia Corporation 的 YUTREPIA(TM)（曲前列尼尔）吸入粉剂于 2024 年 8 月获得美国 FDA 的初步批准，用于治疗患有肺动脉高压 (PAH) 和间质性肺病相关肺动脉高压 (PH-ILD) 的成人患者。该批准基于 3 期 INSPIRE 试验，该试验证明了 YUTREPIA 的安全性和有效性。该公司计划儘早寻求最终批准，以解决 PAH 和 PH-ILD 患者未满足的需求。

以病人为中心的照护和数位健康

以患者为中心的护理措施和数位健康工具的整合，透过提高治疗依从性和疗效，正在影响肺动脉高压药物市场的动态。包括行动应用程式和穿戴式装置在内的数位健康工具能够持续监测心率和血氧水平等生命征象。此外，数位平台促进了患者与医疗团队之间的无缝沟通，从而增强了整体疾病管理。这种整合不仅改善了患者的预后，还使患者能够积极参与肺动脉高压（PAH）的管理，从而提高生活品质并提高医疗服务的效率。此外，AJMC 在 2024 年发表的一篇文章指出，孪生技术有可能彻底改变肺动脉高压 (PH) 的治疗。这项技术涉及创建患者的虚拟模型来模拟病情进展并预测治疗结果。该研究强调了个人化护理和电脑模拟临床试验的潜力，这可以减少传统试验所需的时间和成本。数位健康和​​孪生技术的这些进步正在为肺动脉高压药物市场创造积极的前景，推动成长并改善患者护理。

肺动脉高压（PAH）药物市场细分：

按毒品类别分类：

  • 内皮素受体拮抗剂（ERA）
  • 血管扩张剂
  • 磷酸二酯酶-5（PDE-5）抑制剂
  • 可溶性鸟苷酸环化酶（sGC）刺激剂
  • 钙通道阻断剂（CCB）
  • 前列环素及其类似物
  • 其他的

前列环素和前列环素类似物占据大部分市场份额

前列环素及其类似物在肺动脉高压 (PAH) 药物市场占据主导地位，因其在疾病管理中发挥的关键作用而占据最大的市场份额。这些药物透过扩张血管、降低血管阻力和抑制血小板聚集来发挥作用，从而有效降低肺动脉血压。它们在改善运动能力和延缓病情进展方面已被证实有效，使其成为 PAH 治疗的基石。此外，多种给药方式，例如静脉注射、皮下注射和吸入给药，提高了患者用药的可近性和便利性。持续的研发进步和新型类似物的推出进一步巩固了它们的领先地位，推动了肺动脉高压药物市场的持续成长。

依给药途径分类：

  • 吸入
  • 注射剂
  • 口服

口服给药占业界最大份额

口服给药在肺动脉高压 (PAH) 药物市场中占最大份额，这得益于其在患者便利性和依从性方面的显着优势。口服药物易于给药、非侵入性，可在家中服用，无需前往专门的医疗机构，因此在长期治疗中极具吸引力。这种易用性提高了患者的依从性，这对于管理像 PAH 这样的慢性疾病至关重要。此外，药物製剂的进步提高了口服 PAH 药物的疗效和安全性，从而减少了副作用，并提升了其吸引力。例如，2023 年 12 月，Granules 公司获得了美国食品药物管理局 (FDA) 批准其仿製药 Revatio，该药物用于治疗肺动脉高压 (PAH)。本产品与 Viatris 的西地那非口服混悬液（10 毫克/毫升）具有生物等效性和治疗等效性。 Granules 公司表示，该药物旨在增强 PAH 患者的运动能力并延缓临床恶化。

按最终用户分类：

  • 医院
  • 诊所
  • 其他的

医院是肺动脉高压 (PAH) 药物市场的主要终端用户，在疾病的诊断、治疗和持续管理中发挥着至关重要的作用。医院配备先进的诊断工具以及专业的心臟病学和肺病学科室，有助于准确识别 PAH，从而实现及时有效的干预。医院管理各种 PAH 药物，包括先进的生物製剂和联合疗法，确保为患者提供全面的护理。此外，医院经常参与临床试验和研究项目，推动创新和新疗法的开发。医院集中化的基础设施和多学科协作模式极大地促进了 PAH 药物在市场上的成长和应用。

诊所是肺动脉高压 (PAH) 药物市场的重要终端用户，为 PAH 患者提供便利且持续的照护。这些门诊机构提供常规监测、药物管理和个人化治疗方案，从而提高患者的依从性和疗效。诊所通常与专科医生合作，使用各种 PAH 药物（包括口服药物和注射药物）提供全面的护理。诊所的便利性和本地化布局使其成为 PAH 等慢性疾病管理的关键，确保患者能够及时调整治疗方案。此外，诊所还透过拓展 PAH 药物的分销管道以及推动患者教育和支持计划，促进市场成长。

按地区划分：

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

北美领先市场，占据最大的肺动脉高压药物市场份额

该报告还对所有主要区域市场进行了全面分析，包括北美（美国和加拿大）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告指出，北美是肺动脉高压 (PAH) 药物最大的区域市场。

北美在肺动脉高压 (PAH) 药物市场中占据领先地位，由于几个关键因素占据了最大的市场份额。该地区拥有高度先进的医疗基础设施和广泛的专业医疗设施，从而能够有效诊断和治疗 PAH。根据肺动脉高压药物市场概况，心血管和呼吸系统疾病的盛行率上升推动了整个地区对 PAH 药物的需求。此外，北美是大型製药公司的所在地，这些公司在研发方面投入巨资，促进创新和新疗法的推出。有利的监管框架和大量的医疗资金进一步支持了市场成长。此外，对 PAH 的认识和教育程度的提高有助于早期发现和提高治疗率，巩固了北美在市场上的主导地位。例如，2023 年 9 月，范德比尔特大学的研究人员开发了一种新药 VU6047534，用于治疗肺动脉高压，且不会产生严重的神经系统副作用。该药物标靶作用于心臟和肺部的血清素2B受体，促进器官癒合，并可能逆转心臟病发作造成的伤害。这种化合物不会进入大脑，代表着一种有望治疗肺动脉高压（PAH）的疗法。这项研究由美国国立卫生研究院和范德堡大学资助。

（请注意，这只是关键参与者的部分列表，完整列表在报告中提供。）

  • 肺动脉高压 (PAH) 药物市场竞争激烈，许多製药公司竞相透过开发创新疗法争夺市场份额。市场日益关注先进疗法，例如联合疗法和标靶生物製剂，这些疗法能够提高疗效并改善患者预后。各公司正大力投资研发，以推出新药并增强现有疗法。定价策略、监管审批和专利到期情况对市场动态产生重大影响。此外，仿製药供应的日益充足也加剧了竞争，而市场领导者则利用强大的分销网络和临床试验结果来保持其领先地位。

本报告回答的关键问题

  • 2024 年全球肺动脉高压 (PAH) 药物市场规模是多少
  • 2025 年至 2033 年期间全球肺动脉高压 (PAH) 药物市场的预期成长率是多少
  • 推动全球肺动脉高压（PAH）药物市场的关键因素有哪些
  • COVID-19 对全球肺动脉高压 (PAH) 药物市场有何影响
  • 根据药物类别，全球肺动脉高压 (PAH) 药物市场如何划分
  • 根据给药途径，全球肺动脉高压 (PAH) 药物市场分布如何
  • 全球肺动脉高压（PAH）药物市场的主要区域有哪些
  • 全球肺动脉高压（PAH）药物市场的主要参与者/公司有哪些

本报告回答的关键问题

  • 2024年全球肺动脉高压 (PAH) 药物市场规模？ 2025-2033年全球肺动脉高压 (PAH) 药物市场的预期成长率为何？
  • 推动全球肺动脉高压 (PAH) 药物市场发展的关键因素有哪些？
  • COVID-19 对全球肺动脉高压 (PAH) 药物市场有何影响？
  • 根据药物类别，全球肺动脉高压 (PAH) 药物市场如何分布？
  • 根据给药途径，全球肺动脉高压 (PAH) 药物市场分布如何？
  • 全球肺动脉高压 (PAH) 药物市场的主要区域有哪些？
  • 全球肺动脉高压 (PAH) 药物市场的主要参与者/公司有哪些？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球肺动脉高压（PAH）药物市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依药品类别

  • 内皮素受体拮抗剂（ERA）
  • 血管扩张剂
  • 磷酸二酯酶-5（PDE-5）抑制剂
  • 可溶性鸟苷酸环化酶（sGC）刺激剂
  • 钙通道阻断剂（CCB）
  • 前列环素及其类似物
  • 其他的

第七章：市场区隔：依行政途径

  • 吸入
  • 注射剂
  • 口服

第八章：市场区隔：按最终用户

  • 医院
  • 诊所
  • 其他的

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第十章：SWOT分析

第 11 章：价值链分析

第 12 章：波特五力分析

第十三章：价格分析

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Actelion Pharmaceuticals Ltd (Johnson & Johnson)
    • Arena Pharmaceuticals Inc.
    • AstraZeneca PLC
    • Bayer Aktiengesellschaft
    • Daiichi Sankyo Company Limited
    • Gilead Science Inc.
    • GlaxoSmithKline PLC
    • Merck KGaA
    • Novartis International AG
    • Pfizer Inc.
    • United Therapeutics Corporation
Product Code: SR112025A2399

The global pulmonary arterial hypertension (PAH) drugs market size reached USD 8.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 12.0 Billion by 2033, exhibiting a growth rate (CAGR) of 4.4% during 2025-2033. The market is experiencing significant growth mainly driven by advancements in targeted therapies, increasing prevalence of PAH and growing awareness. Expanding research and development (R&D) efforts are also creating a positive outlook for the market further across the world.

Pulmonary Arterial Hypertension Drugs Market Trends:

Increased Use of Combination Therapies

Physicians are increasingly adopting combination therapies to enhance treatment efficacy in Pulmonary Arterial Hypertension (PAH). By prescribing a mix of drugs from different therapeutic classes, they target multiple biological pathways involved in PAH. This multifaceted approach helps to manage symptoms, slow disease progression, and improve overall patient outcomes more effectively. Additionally, combination therapies can allow for lower doses of individual medications, potentially reducing side effects and enhancing patient adherence. As clinical evidence supports their benefits, combination treatments are becoming the standard of care in PAH management, driving market growth and innovation. For instance, in March 2024, Johnson & Johnson's OPSYNVI(R) (macitentan and tadalafil) was approved by the U.S. FDA as the first once-daily single-tablet combination therapy for adults with pulmonary arterial hypertension (PAH). This approval is based on the successful Phase 3 A DUE study, which showed significant pulmonary hemodynamic improvement. OPSYNVI(R) combines two established treatments into a single tablet, aligning with clinical guideline recommendations for early combination therapy.

Rising Focus on Innovative Therapies

The rising focus on innovative therapies in Pulmonary Arterial Hypertension (PAH) is driving the exploration of gene therapies and targeted biologics, which aim to address the root causes of the disease. Gene therapies hold the potential to modify genetic factors involved in PAH, offering a long-term solution rather than just symptom management. Targeted biologics, on the other hand, focus on specific molecular pathways contributing to disease progression, allowing for more personalized and effective treatments. These novel approaches could lead to significant breakthroughs in disease modification, improving survival rates and overall quality of life for PAH patients. In line with this, in August 2024, Liquidia Corporation's YUTREPIA(TM) (treprostinil) inhalation powder received tentative approval from the U.S. FDA to treat adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The approval is based on the Phase 3 INSPIRE trial, which demonstrated the safety and efficacy of YUTREPIA. The company plans to seek final approval at the earliest to address the unmet needs of PAH and PH-ILD patients.

Patient-Centered Care and Digital Health

Patient-centered care initiatives and the integration of digital health tools are influencing the pulmonary arterial hypertension drugs market dynamics by enhancing treatment adherence and outcomes. Digital health tools, including mobile apps and wearable devices, enable continuous monitoring of vital signs such as heart rate and oxygen levels. Additionally, digital platforms facilitate seamless communication between patients and medical teams, enhancing overall disease management. This integration not only improves patient outcomes but also empowers individuals to take an active role in managing their PAH, leading to increased quality of life and more efficient healthcare delivery. Moreover, in an article published by AJMC in 2024, it was suggested that twin technology has the potential to revolutionize pulmonary hypertension (PH) treatment. This technology involves creating virtual models of patients to simulate disease progression and predict treatment outcomes. The study emphasizes the potential for personalized care and in silico clinical trials, which could reduce the time and costs associated with traditional trials. These advancements in digital health and twin technology are creating a positive pulmonary arterial hypertension drugs market outlook, driving growth and improving patient care.

Pulmonary Arterial Hypertension (PAH) Drugs Market Segmentation:

Breakup by Drug Class:

  • Endothelin Receptor Antagonists (ERAs)
  • Vasodilators
  • Phosphodiesterase-5 (PDE-5) Inhibitors
  • Soluble Guanylate Cyclase (sGC) Stimulators
  • Calcium Channel Blockers (CCBs)
  • Prostacyclin and Prostacyclin Analogs
  • Others

Prostacyclin and Prostacyclin Analogs accounts for the majority of the market share

Prostacyclin and prostacyclin analogs dominate the pulmonary arterial hypertension (PAH) drugs market, accounting for the largest market share due to their critical role in managing the disease. These medications work by dilating blood vessels, reducing vascular resistance, and inhibiting platelet aggregation, which effectively lowers blood pressure in the pulmonary arteries. Their proven efficacy in improving exercise capacity and delaying disease progression makes them a cornerstone of PAH therapy. Additionally, the availability of various administration forms, such as intravenous, subcutaneous, and inhaled options, enhances their accessibility and convenience for patients. Ongoing advancements and the introduction of newer analogs further solidify their leading position, driving sustained pulmonary arterial hypertension drugs market growth.

Breakup by Route of Administration:

  • Inhalation
  • Injectable
  • Oral Administration

Oral Administration holds the largest share of the industry

Oral administration holds the largest share of the pulmonary arterial hypertension (PAH) drugs market due to its significant advantages in patient convenience and adherence. Oral medications are easy to administer, non-invasive, and can be taken at home without the need for specialized medical facilities, making them highly attractive for long-term treatment. This ease of use enhances patient compliance, which is crucial for managing a chronic condition like PAH. Additionally, advancements in pharmaceutical formulations have improved the efficacy and safety profiles of oral PAH drugs, thereby reducing side effects and increasing their appeal. For instance, in December 2023, Granules obtained approval from the U.S. Food and Drug Administration for its generic version of Viatris Specialty's Revatio, a treatment for pulmonary arterial hypertension (PAH). The product is bioequivalent and therapeutically equivalent to Viatris's Sildenafil for oral suspension, 10 mg/ml. Granules stated that the drug is intended to enhance exercise ability and delay clinical worsening in PAH patients.

Breakup by End User:

  • Hospitals
  • Clinics
  • Others

Hospitals are a primary end user in the Pulmonary Arterial Hypertension (PAH) drugs market, playing a crucial role in diagnosis, treatment, and ongoing management of the condition. Equipped with advanced diagnostic tools and specialized cardiology and pulmonology departments, hospitals facilitate the accurate identification of PAH, enabling timely and effective intervention. They administer a wide range of PAH medications, including advanced biologics and combination therapies, ensuring comprehensive patient care. Additionally, hospitals often participate in clinical trials and research initiatives, driving innovation and the development of new treatments. The centralized infrastructure and multidisciplinary approach in hospitals significantly contribute to the growth and adoption of PAH drugs in the market.

Clinics are essential end users in the Pulmonary Arterial Hypertension (PAH) drugs market, providing accessible and continuous care for patients with PAH. These outpatient facilities offer routine monitoring, medication management, and personalized treatment plans, enhancing patient adherence and outcomes. Clinics often collaborate with specialists to deliver comprehensive care, utilizing a variety of PAH drugs, including oral therapies and injectable medications. The convenience and localized presence of clinics make them pivotal in managing chronic conditions like PAH, ensuring that patients receive timely adjustments to their treatment regimens. Additionally, clinics contribute to market growth by increasing the distribution channels for PAH medications and fostering patient education and support initiatives.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest pulmonary arterial hypertension drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for pulmonary arterial hypertension (PAH) drugs.

North America leads the Pulmonary Arterial Hypertension (PAH) drugs market, accounting for the largest market share due to several key factors. The region benefits from a highly advanced healthcare infrastructure and widespread access to specialized medical facilities, enabling effective diagnosis and treatment of PAH. According to pulmonary arterial hypertension drugs market overview, the rising prevalence of cardiovascular and respiratory diseases drives the demand for PAH medications across the region. Additionally, North America is home to major pharmaceutical companies that invest heavily in research and development (R&D), fostering innovation and the introduction of new therapies. Favorable regulatory frameworks and substantial healthcare funding further support market growth. Moreover, increased awareness and education about PAH contribute to the early detection and higher treatment rates, solidifying North America's dominant market position. For instance, in September 2023, researchers at Vanderbilt University developed a new drug, VU6047534, to treat pulmonary arterial hypertension without serious neurological side effects. The drug targets serotonin 2B receptors in the heart and lungs, promoting organ healing and potentially reversing damage from heart attacks. The compound, designed to stay out of the brain, represents a promising therapy for PAH. The research was funded by the National Institutes of Health and Vanderbilt University.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the pulmonary arterial hypertension (PAH) drugs industry include Actelion Pharmaceuticals Ltd (Johnson & Johnson), Arena Pharmaceuticals Inc., AstraZeneca PLC, Bayer Aktiengesellschaft, Daiichi Sankyo Company Limited, Gilead Science Inc., GlaxoSmithKline PLC, Merck KGaA, Novartis International AG, Pfizer Inc. and United Therapeutics Corporation.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • The Pulmonary Arterial Hypertension (PAH) drugs market is highly competitive, with numerous pharmaceutical companies vying for market share through the development of innovative therapies. The market is characterized by a growing focus on advanced treatments, such as combination therapies and targeted biologics, which offer improved efficacy and patient outcomes. Companies are investing heavily in research and development to introduce novel drugs and enhance existing treatments. Pricing strategies, regulatory approvals, and patent expirations significantly influence market dynamics. Additionally, the increasing availability of generics intensifies competition, while market leaders leverage strong distribution networks and clinical trial results to maintain their positions.

Key Questions Answered in This Report

  • 1.What was the size of the global Pulmonary Arterial Hypertension (PAH) drugs market in 2024?
  • 2.What is the expected growth rate of the global Pulmonary Arterial Hypertension (PAH) drugs market during 2025-2033?
  • 3.What are the key factors driving the global Pulmonary Arterial Hypertension (PAH) drugs market?
  • 4.What has been the impact of COVID-19 on the global Pulmonary Arterial Hypertension (PAH) drugs market?
  • 5.What is the breakup of the global Pulmonary Arterial Hypertension (PAH) drugs market based on the drug class?
  • 6.What is the breakup of the global Pulmonary Arterial Hypertension (PAH) drugs market based on the route of administration?
  • 7.What are the key regions in the global Pulmonary Arterial Hypertension (PAH) drugs market?
  • 8.Who are the key players/companies in the global Pulmonary Arterial Hypertension (PAH) drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pulmonary Arterial Hypertension (PAH) Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Endothelin Receptor Antagonists (ERAs)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Vasodilators
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Phosphodiesterase-5 (PDE-5) Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Soluble Guanylate Cyclase (sGC) Stimulators
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Calcium Channel Blockers (CCBs)
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Prostacyclin and Prostacyclin Analogs
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Inhalation
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Injectable
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Oral Administration
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Actelion Pharmaceuticals Ltd (Johnson & Johnson)
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Arena Pharmaceuticals Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 AstraZeneca PLC
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Bayer Aktiengesellschaft
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Daiichi Sankyo Company Limited
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Gilead Science Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 GlaxoSmithKline PLC
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Merck KGaA
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Novartis International AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Pfizer Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 United Therapeutics Corporation
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Pulmonary Arterial Hypertension Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Drug Class (in %), 2024
  • Figure 4: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Route of Administration (in %), 2024
  • Figure 5: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by End User (in %), 2024
  • Figure 6: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Region (in %), 2024
  • Figure 7: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 8: Global: Pulmonary Arterial Hypertension Drugs (Endothelin Receptor Antagonists - ERAs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Pulmonary Arterial Hypertension Drugs (Endothelin Receptor Antagonists - ERAs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Pulmonary Arterial Hypertension Drugs (Vasodilators) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Pulmonary Arterial Hypertension Drugs (Vasodilators) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Pulmonary Arterial Hypertension Drugs (Phosphodiesterase-5 - PDE-5 Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Pulmonary Arterial Hypertension Drugs (Phosphodiesterase-5 - PDE-5 Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Pulmonary Arterial Hypertension Drugs (Soluble Guanylate Cyclase- sGC Stimulators) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Pulmonary Arterial Hypertension Drugs (Soluble Guanylate Cyclase- sGC Stimulators) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Pulmonary Arterial Hypertension Drugs (Calcium Channel Blockers - CCBs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Pulmonary Arterial Hypertension Drugs (Calcium Channel Blockers - CCBs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Pulmonary Arterial Hypertension Drugs (Prostacyclin and Prostacyclin Analogs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Pulmonary Arterial Hypertension Drugs (Prostacyclin and Prostacyclin Analogs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Pulmonary Arterial Hypertension Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Pulmonary Arterial Hypertension Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Pulmonary Arterial Hypertension Drugs (Inhalation) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Pulmonary Arterial Hypertension Drugs (Inhalation) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Pulmonary Arterial Hypertension Drugs (Injectable) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Pulmonary Arterial Hypertension Drugs (Injectable) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Pulmonary Arterial Hypertension Drugs (Oral Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Pulmonary Arterial Hypertension Drugs (Oral Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Pulmonary Arterial Hypertension Drugs (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Pulmonary Arterial Hypertension Drugs (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Pulmonary Arterial Hypertension Drugs (Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Pulmonary Arterial Hypertension Drugs (Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Pulmonary Arterial Hypertension Drugs (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Pulmonary Arterial Hypertension Drugs (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: North America: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: North America: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: United States: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: United States: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Canada: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Canada: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Asia Pacific: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Asia Pacific: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: China: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: China: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Japan: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Japan: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: India: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: India: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: South Korea: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: South Korea: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Australia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Australia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Indonesia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Indonesia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Europe: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Europe: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Germany: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Germany: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: France: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: France: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: United Kingdom: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: United Kingdom: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Italy: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Italy: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Spain: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Spain: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Russia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Russia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Latin America: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Latin America: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Brazil: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Brazil: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Mexico: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Mexico: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Middle East and Africa: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Middle East and Africa: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Global: Pulmonary Arterial Hypertension Drugs Industry: SWOT Analysis
  • Figure 83: Global: Pulmonary Arterial Hypertension Drugs Industry: Value Chain Analysis
  • Figure 84: Global: Pulmonary Arterial Hypertension Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pulmonary Arterial Hypertension Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 3: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 4: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 5: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Pulmonary Arterial Hypertension Drugs Market Structure
  • Table 7: Global: Pulmonary Arterial Hypertension Drugs Market: Key Players